Scrip's Guide To Spinal Muscular Atrophy Therapies
Executive Summary
INFOGRAPHIC: The prospects for patients with spinal muscular atrophy, the leading cause of genetic death in infants, have been revolutionized by the arrival of the first approved drug for the disease, Biogen’s blockbuster Spinraza. Now, other firms with equally revolutionary product candidates are giving chase. Scrip takes a look at the main contenders.
You may also be interested in...
Takeda Highlights Rare Neurological Disorder Programs In Wave 1
Seeing significant unmet medical needs and insufficiently met needs in narcolepsy and rare types of epilepsy, Takeda has shifted its neuroscience focus.
Durability Seen With Novartis, Roche SMA Therapies Heading For Market
Novartis and Roche have announced additional interim clinical data as their candidate spinal muscular atrophy therapies near the marketplace.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.